ascorbic-acid and Teratogenesis

ascorbic-acid has been researched along with Teratogenesis* in 1 studies

Other Studies

1 other study(ies) available for ascorbic-acid and Teratogenesis

ArticleYear
A novel screening test to predict the developmental toxicity of drugs using human induced pluripotent stem cells.
    The Journal of toxicological sciences, 2020, Volume: 45, Issue:4

    In vitro human induced pluripotent stem (iPS) cells testing (iPST) to assess developmental toxicity, e.g., the induction of malformation or dysfunction, was developed by modifying a mouse embryonic stem cell test (EST), a promising animal-free approach. The iPST evaluates the potential risks and types of drugs-induced developmental toxicity in humans by assessing three endpoints: the inhibitory effects of the drug on the cardiac differentiation of iPS cells and on the proliferation/survival of iPS cells and human fibroblasts. In the present study, the potential developmental toxicity of drugs was divided into three classes (1: non-developmentally toxic, 2: weakly developmentally toxic and 3: strongly developmentally toxic) according to the EST criteria. In addition, the type of developmental toxicity of drugs was grouped into three types (1: non-effective, 2: embryotoxic [inducing growth retardation/dysfunction]/deadly or 3: teratogenic [inducing malformation]/deadly) by comparing the three endpoints. The present study was intended to validate the clinical predictability of the iPST. The traditionally developmentally toxic drugs of aminopterin, methotrexate, all-trans-retinoic acid, thalidomide, tetracycline, lithium, phenytoin, 5-fluorouracil, warfarin and valproate were designated as class 2 or 3 according to the EST criteria, and their developmental toxicity was type 3. The non-developmentally toxic drugs of ascorbic acid, saccharin, isoniazid and penicillin G were designated as class 1, and ascorbic acid, saccharin and isoniazid were grouped as type 1 while penicillin G was type 2 but not teratogenic. These results suggest that the iPST is useful for predicting the human developmental toxicity of drug candidates in a preclinical setting.

    Topics: Aminopterin; Animals; Ascorbic Acid; Cell Differentiation; Cell Proliferation; Cells, Cultured; Drug Evaluation, Preclinical; Fibroblasts; Humans; Isoniazid; Methotrexate; Mice; Pluripotent Stem Cells; Saccharin; Teratogenesis; Toxicity Tests; Tretinoin

2020